Briacell Therapeutics Corp · TSX:BCT
Briacell Therapeutics — Investor Presentation (April 2021)
17 slides from Briacell Therapeutics's investor presentation, April 2021
Slide 1: The Future of Cancer Immunotherapy
The Future of Cancer Immunotherapy BriaCell Therapeutics Corp. Nasdaq: BCTX, BCTXW TSXV: BCT Investor Presentation Spring 2021 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements BriaCell Therapeutics Corp. (“BriaCell”) Except for historical information, this presentation contains forward-looking statements, which reflect BriaCell’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and un
Slide 3: Capitalization Structure
Capitalization Structure Nasdaq: BCTX, BCTXW Stock Symbols: TSXV: BCT Share Price (as of 3/18/21): US$3.88 Shares Outstanding: 7,536,667 Market Cap: US$27M Options (US$5.42 WAEP): 637,352 Warrants (US$5.13 WAEP): 6,871,347 Cash (pro-forma for 3/12/21 $28.7M financing, $28.7M excluding underwriting d
Slide 4: BriaCell Corporate Highlights
BriaCell Corporate Highlights BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSXV: BCT) is a clinical stage immunotherapy company developing treatments that boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors Lead drug candidate Bria-IMT™ is targeting third-l
Slide 5: BriaCell’s Expert Drug Development & Financial Team
BriaCell’s Expert Drug Development & Financial Team William V. Williams, MD, FACP, President & CEO, Director Jamieson Bondarenko, CFA, CMT, Chairman of the Board Former VP, Exploratory Development, Incyte Corporation Previously Principal and Managing Director of the Equity Capital Markets group
Slide 6: BriaCell Pipeline
BriaCell Pipeline Therapeutic Indication Preclinical Phase I Phase II Phase III Anticipated Milestones Bria-IMT™ + Incyte Advanced Breast Cancer Phase I/II Further safety and efficacy Compounds (3rd+ line) data through 2021 Bria-OTS™ Breast Cancer IND filing 2021 NICL1* Prostate Cancer IND Filing 20
Slide 7: BriaCell’s Patented Immunotherapy: Bria-IMT™
BriaCell’s Patented Immunotherapy: Bria-IMT™ Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. Antigens Tumor Destruction CD8+ Bria-IMT™ CD4+ GM-C
Slide 8: Bria-IMT™ – Phase I/IIa Efficacy in Breast Cancer
Bria-IMT™ – Phase I/IIa Efficacy in Breast Cancer Mechanism of Action & Proof-of-Concept 4 patients treated by Dr. Wiseman in 2004-2005 (original patients), including one remarkable responder. 23 patients were dosed in 2017-2018 (Phase I/IIa), all very heavily pre-treated (with chemotherapy).
Slide 9: Bria-IMT™ in Combination with Immune Checkpoint Inhibitors
Bria-IMT™ in Combination with Immune Checkpoint Inhibitors How Do Checkpoint Inhibitors Work? • PD-L1 molecules block immune cells from attacking cancer cells • Immune checkpoint inhibitors are designed to neutralize this immune suppression in cancer patients Why did we combine Bria-IMT™ with immune
Slide 10: Bria-IMT™ + Immune Checkpoint Inhibitor Combination Study Data
Bria-IMT™ + Immune Checkpoint Inhibitor Combination Study Data Phase I/IIa Combination Study in Advanced Breast Cancer Patients were treated with the combination of Bria-IMT™ and anti-PD-1 antibody KEYTRUDA®. An excellent safety and tolerability profile on the first 11 patients was observed. A
Slide 11: Bria-IMT™ + Immune Checkpoint Inhibitor: Remarkable Responder
Bria-IMT™ + Immune Checkpoint Inhibitor: Remarkable Responder Tumor behind the left eye causing proptosis completely resolves Six months Baseline On Treatment Scans Scans Complete resolution of orbital tumor in a heavily pre-treated patient with 2 HLA matches and a grade II tumor supports remarkable
Slide 12: Summary: Bria-IMT™ in Advanced Breast Cancer Trials
Summary: Bria-IMT™ in Advanced Breast Cancer Trials 1 Proof-of-concept trial 2 Phase I/IIa monotherapy 3 Phase I/IIa combination w/Keytruda® **Disease **Disease POC trial (2004-2006) HLA *Disease Control in HLA *Disease Control in Patients Patients match Control immune match Control immune Patients
Slide 13: Summary: Bria-IMT™ in Advanced Breast Cancer Trials
Summary: Bria-IMT™ in Advanced Breast Cancer Trials 1&2 Phase I/IIa monotherapy 3 Phase I/IIa combination with Keytruda® Patient characteristics Patient characteristics No HLA ≥1 HLA No HLA ≥1 HLA ≥2 HLA ≥2 HLA matches matches matches matches (n=7) matches (n=5) matches (n=6) (n=4) (n=7) (n=20) Age
Slide 14: Bria-IMT™ in Grade I/II Tumors
Bria-IMT™ in Grade I/II Tumors Breast Cancer Grade Correlates with Response Cell Lines Bria-IMT™ is derived from a grade II (moderately differentiated) breast cancer. Genes expressed by Bria-IMT™ match best with grade I/II-derived Breast Cancer Cell Lines ~40% of recurrent breast cancers are g
Slide 15: Introducing… Bria-OTS™
Introducing… Bria-OTS™ Bria-OTS™: Off-The-Shelf Personalized Immunotherapy Confirmation of “Matching Hypothesis” resulted in BriaCell’s “OTS” strategy • Cooperative Research and Development Agreement with the National Cancer Institute, part of the National Institutes of Health • We believe our treat
Slide 16: Timeline for Key Clinical Programs in Breast Cancer
Timeline for Key Clinical Programs in Breast Cancer Anticipated Milestones 2021 2022 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Bria-IMT™ + Incyte Compounds – Pre-Registration Study Data Bria-OTS™ – Authorization by FDA; 1st Patient Dosed Bria-OTS™ – Pre-Registration Study Data Registration Study – Br
Slide 17: Thank you
BriaCell Therapeutics Corp. info@BriaCell.com BriaCell.com 1-888-485-6340 Thank you 17
BriaCell Therapeutics — Investor Presentation (April 2021) on 6ix